Despite a slower start in the immuno-oncology arena, China appears to have surpassed its Western counterparts in building a strong research pipeline of specialised CAR-T therapies. Next month, with the help of data, we’ll track the rise of cell therapy research, and more specifically CAR-Ts, in China and how that compares to the rest of the world.
With between 100 and 400 million dengue fever infections each year, pharma manufacturers need to overcome several obstacles to developing antiviral treatments and vaccines. In July, we’ll take a look at the candidates in the clinic, and what can be expected in the pipeline in the near future.
All this plus the latest trends and innovations in the pharma industry, as well as up-to-date analysis and insight from GlobalData experts.
Editor | Manasi Vaidya
Writers | Mengying Du, Urte Fultinaviciute, Isabeau van Halm, Saywah Mahmood, William Newton, Mirela Petkova, Adam Zamecnik
Magazine Designer | Maria Gimenez, Martina Labaiova
Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Will Ingham
Lead Designer | John Hammond
Publisher | Susanne Hauner
Sales Manager | Tom McCormick
+44 207 8669440
Pharma Technology Focus is powered by H5mag
Read past issues of Pharma Technology Focus HERE
Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.